Literature DB >> 18332268

Human apolipoprotein A-I gene transfer reduces the development of experimental diabetic cardiomyopathy.

Sophie Van Linthout1, Frank Spillmann, Alexander Riad, Christiane Trimpert, Joke Lievens, Marco Meloni, Felicitas Escher, Elena Filenberg, Okan Demir, Jun Li, Mehdi Shakibaei, Ingolf Schimke, Alexander Staudt, Stephan B Felix, Heinz-Peter Schultheiss, Bart De Geest, Carsten Tschöpe.   

Abstract

BACKGROUND: The hallmarks of diabetic cardiomyopathy are cardiac oxidative stress, intramyocardial inflammation, cardiac fibrosis, and cardiac apoptosis. Given the antioxidative, antiinflammatory, and antiapoptotic potential of high-density lipoprotein (HDL), we evaluated the hypothesis that increased HDL via gene transfer (GT) with human apolipoprotein (apo) A-I, the principal apolipoprotein of HDL, may reduce the development of diabetic cardiomyopathy. METHODS AND
RESULTS: Intravenous GT with 3x10(12) particles/kg of the E1E3E4-deleted vector Ad.hapoA-I, expressing human apoA-I, or Ad.Null, containing no expression cassette, was performed 5 days after streptozotocin (STZ) injection. Six weeks after apoA-I GT, HDL cholesterol levels were increased by 1.6-fold (P<0.001) compared with diabetic controls injected with the Ad.Null vector (STZ-Ad.Null). ApoA-I GT and HDL improved LV contractility in vivo and cardiomyocyte contractility ex vivo, respectively. Moreover, apoA-I GT was associated with decreased cardiac oxidative stress and reduced intramyocardial inflammation. In addition, compared with STZ-Ad.Null rats, cardiac fibrosis and glycogen accumulation were reduced by 1.7-fold and 3.1-fold, respectively (P<0.05). Caspase 3/7 activity was decreased 1.2-fold (P<0.05), and the ratio of Bcl-2 to Bax was upregulated 1.9-fold (P<0.005), translating to 2.1-fold (P<0.05) reduced total number of cardiomyocytes with apoptotic characteristics and 3.0-fold (P<0.005) reduced damaged endothelial cells compared with STZ-Ad.Null rats. HDL supplementation ex vivo reduced hyperglycemia-induced cardiomyocyte apoptosis by 3.4-fold (P<0.005). The apoA-I GT-mediated protection was associated with a 1.6-, 1.6-, and 2.4-fold induction of diabetes-downregulated phospho to Akt, endothelial nitric oxide synthase, and glycogen synthase kinase ratio, respectively (P<0.005).
CONCLUSIONS: ApoA-I GT reduced the development of streptozotocin-induced diabetic cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18332268     DOI: 10.1161/CIRCULATIONAHA.107.710830

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  49 in total

1.  Absence of mannose-binding lectin prevents hyperglycemic cardiovascular complications.

Authors:  Vasile I Pavlov; Laura R La Bonte; William M Baldwin; Maciej M Markiewski; John D Lambris; Gregory L Stahl
Journal:  Am J Pathol       Date:  2011-11-08       Impact factor: 4.307

2.  Apolipoprotein mimetic peptides: Mechanisms of action as anti-atherogenic agents.

Authors:  David O Osei-Hwedieh; Marcelo Amar; Dmitri Sviridov; Alan T Remaley
Journal:  Pharmacol Ther       Date:  2010-12-21       Impact factor: 12.310

Review 3.  High density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease.

Authors:  Meliana Riwanto; Ulf Landmesser
Journal:  J Lipid Res       Date:  2013-07-20       Impact factor: 5.922

4.  Abnormal glucose and lipid control in non-ischemic left ventricular dysfunction.

Authors:  Danilo Neglia; Tiziana Sampietro; Cecilia Vecoli; Riccardo Liga; Giuseppe Rossi; Elena Filidei; Federico Bigazzi; Patricia Iozzo; Daniela Giannessi; Antonio L'Abbate; Daniele Rovai
Journal:  J Nucl Cardiol       Date:  2012-08-10       Impact factor: 5.952

5.  Cannabidiol protects against high glucose-induced oxidative stress and cytotoxicity in cardiac voltage-gated sodium channels.

Authors:  Mohamed A Fouda; Mohammad-Reza Ghovanloo; Peter C Ruben
Journal:  Br J Pharmacol       Date:  2020-03-10       Impact factor: 8.739

Review 6.  Heart Failure with Preserved Ejection Fraction and Future Pharmacological Strategies: a Glance in the Crystal Ball.

Authors:  Carsten Tschöpe; Sophie Van Linthout; Behrouz Kherad
Journal:  Curr Cardiol Rep       Date:  2017-08       Impact factor: 2.931

7.  Abnormal cannabidiol confers cardioprotection in diabetic rats independent of glycemic control.

Authors:  Asmaa I Matouk; Ashraf Taye; Mohamed A El-Moselhy; Gehan H Heeba; Abdel A Abdel-Rahman
Journal:  Eur J Pharmacol       Date:  2017-12-20       Impact factor: 4.432

8.  Nerve growth factor gene therapy using adeno-associated viral vectors prevents cardiomyopathy in type 1 diabetic mice.

Authors:  Marco Meloni; Betty Descamps; Andrea Caporali; Lorena Zentilin; Ilaria Floris; Mauro Giacca; Costanza Emanueli
Journal:  Diabetes       Date:  2012-01       Impact factor: 9.461

Review 9.  HDL therapy today: from atherosclerosis, to stent compatibility to heart failure.

Authors:  C R Sirtori; M Ruscica; L Calabresi; G Chiesa; R Giovannoni; J J Badimon
Journal:  Ann Med       Date:  2019 Nov - Dec       Impact factor: 4.709

10.  Successful treatment of established heart failure in mice with recombinant HDL (Milano).

Authors:  Joseph Pierre Aboumsallem; Mudit Mishra; Ruhul Amin; Ilayaraja Muthuramu; Herman Kempen; Bart De Geest
Journal:  Br J Pharmacol       Date:  2018-09-19       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.